These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23242463)

  • 1. Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.
    Abedi MR; Doverud AC
    J Vis Exp; 2012 Dec; (70):e4414. PubMed ID: 23242463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: maintained in vitro quality over 7-day storage.
    Ohlsson S; Diedrich B; Uhlin M; Sandgren P
    Vox Sang; 2018 Oct; 113(7):611-621. PubMed ID: 30156292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system.
    Plaza EM; Lozano ML; Guiu IS; Egea JM; Vicente V; De Terán LC; Rivera J
    Blood Transfus; 2012 Oct; 10(4):480-9. PubMed ID: 22682335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
    BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preparation of pooled granulocytes concentrates from whole blood buffy coats (PGC) as an alternative to apheresis].
    Mastronardi R; Cleophax S; Begué S; Hurtado-Nedelec M; Gross S; Bocquet T; Djoudi R
    Transfus Clin Biol; 2019 Sep; 26(3):164-170. PubMed ID: 31400933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis.
    Feys HB; Devloo R; Sabot B; De Pourcq K; Coene J; Compernolle V
    Vox Sang; 2017 Nov; 112(8):751-758. PubMed ID: 28960339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.
    Johnson L; Loh YS; Kwok M; Marks DC
    Transfus Med; 2013 Apr; 23(2):121-9. PubMed ID: 23480103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates.
    Singh S; Shams Hakimi C; Jeppsson A; Hesse C
    Transfus Apher Sci; 2017 Dec; 56(6):870-874. PubMed ID: 29126740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
    Sandgren P; Diedrich B
    Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.
    Rosskopf K; Helmberg W; Schlenke P
    Transfusion; 2020 Sep; 60(9):2058-2066. PubMed ID: 32619068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hematologic values and transforming growth factor-beta and insulin-like growth factor concentrations in platelet concentrates obtained by use of buffy coat and apheresis methods from equine blood.
    Sutter WW; Kaneps AJ; Bertone AL
    Am J Vet Res; 2004 Jul; 65(7):924-30. PubMed ID: 15281650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of buffy coat-derived granulocytes for clinical use: a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products.
    van de Geer A; Gazendam RP; Tool AT; van Hamme JL; de Korte D; van den Berg TK; Zeerleder SS; Kuijpers TW
    Vox Sang; 2017 Feb; 112(2):173-182. PubMed ID: 28120426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
    Reikvam H; Marschner S; Apelseth TO; Goodrich R; Hervig T
    Blood Transfus; 2010 Jul; 8(3):186-92. PubMed ID: 20671879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
    Ali SF
    Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible implication of sterile connecting device in contamination of pooled platelet concentrates.
    Mertens G; Muylle L; Goossens H
    Transfus Sci; 1997 Sep; 18(3):387-92. PubMed ID: 10175151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
    Lozano ML; Rivera J; Vicente V
    Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the quality of hemoderivatives obtained using a buffy-coat extraction system with a top-and-bottom technique (Optipress II)].
    Hurtado C; Bonanad S; Soler MA; Mirabet V; Blasco I; Planelles MD; de Miguel A
    Sangre (Barc); 1999 Oct; 44(5):319-26. PubMed ID: 10618907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.